Artikel
Leaders in focus: Exclusive interviews from ISPOR Europe 2025
At ISPOR Europe 2025 in Glasgow – the leading conference for Health Economics and Outcomes Research (HEOR) – we had the privilege of connecting with global healthcare leaders to explore today’s most pressing challenges and emerging opportunities in the field. This exclusive collection of expert interviews delves into critical topics, including the complexities of EU HTA, country-specific strategies, and the latest global policy changes shaping innovation and patient access. Discover insights from the forefront of healthcare innovation and policy to stay ahead.
Tackling market access and global policies: EU HTA Regulation in focus
Herbert Altman, Vice President, Market Access & Healthcare Consulting, Europe, at Cencora, and Alexander Natz, Secretary General at EUCOPE, explore the EU HTA Regulation’s role in reducing bureaucracy and improving patient access. At ISPOR Europe 2025, they discussed challenges like patient engagement, the influence of US Most Favored Nation policies, and the need for harmonized processes across Europe to keep the region competitive for pharmaceutical innovation.
Sweden’s perspective on EU HTA: Progress, challenges, and future goals
Niklas Hedberg, Chief Pharmacist of TLV and Co-Chair of the EU HTA Coordinating Group, shares Sweden’s role in the EU HTA Regulation, key milestones achieved, and the vision for 2028. In this interview, he highlights how collaboration, capacity-building, and stakeholder engagement can reduce disparities across member states and improve patient access to innovative therapies.
Expanding the role of health economics in France’s market access
Watch Isabelle Bourget, Pharmacist and Health Economist, and Professor at Institut Gustave Roussy, as she discusses the evolving role of health economic evaluations in France with Jean-Marc Pinguet, Market Access Lead, France and Benelux, at Cencora. Learn about current criteria for drug assessments, comparisons with other countries, and the potential for broader adoption of economic arguments in price negotiations. In this interview, Isabelle explores how these evaluations can support sustainability, innovation, and faster patient access in the French healthcare system.
Additional insights
Article
Navigating global policy shifts: Insights from ISPOR Europe 2025
The global healthcare landscape is rapidly evolving, with Europe’s pharmaceutical industry facing pressures from U.S. policy changes and China’s growing pharmaceutical ecosystem. At ISPOR Europe 2025, our expert Casper Paardekooper, Head of Pricing, Policy and Stakeholder Engagement, had the honor of moderating the symposium, “Navigating Global Policy Shifts: Implications for Europe’s Pharmaceutical Pricing, Market Access, and HTA Landscape,” featuring a panel of esteemed experts. Together, we examined the impact of global policy changes on Europe’s healthcare systems, opportunities for adaptation, and the importance of collaboration to drive innovation.
Article
Harmonizing Health Technology Assessment: PICO consolidation under the EU HTA Regulation
The EU HTA regulation (EU HTAR) is reshaping global market access, bringing both opportunities and challenges for manufacturers. In this exclusive Corporate partner insights interview by ISPOR, Ruairi O'Donnell, Vice President of Market Access and Healthcare Consulting Europe at Cencora, joins Dr. Patti Peeples to explore how the industry can adapt to this new reality. Ruairi shares actionable strategies to navigate the complexities of EU HTA and PICO consolidation. From harmonizing clinical evidence across Europe to addressing unrealistic comparators and leveraging real-world evidence (RWE), this discussion provides a roadmap for success.
Cencora solution
EU Health Technology Assessment (HTA) consulting
As the European Union takes bold strides towards harmonizing and enhancing its healthcare landscape, the implementation of the Joint Clinical Assessment (JCA) stands as a pivotal moment. At Cencora, we help companies at all stages of the EU HTA journey, from early evidence to post-JCA implementation at the national level.
Verbinden Sie sich mit unserem Team
Unser Team aus führenden Value-Experten hat es sich zur Aufgabe gemacht, Evidenz, Wissen zu Richtlinien und Marktinformationen in effektive globale Marktzugangsstrategien umzuwandeln. Wir helfen Ihnen, sich in der komplexen Landschaft des heutigen Gesundheitswesens sicher zurechtzufinden. Kontaktieren Sie uns, um zu erfahren, wie wir Ihre Ziele unterstützen können.
